Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:CELG
gptkb:Acceleron_Pharma |
| gptkbp:activities |
modulates TGF-beta superfamily signaling
|
| gptkbp:appointed_by |
subcutaneous injection
|
| gptkbp:approves |
gptkb:2019
gptkb:FDA |
| gptkbp:clinical_trial |
Phase 3
enhancing quality of life NC T03013998 NC T03482560 NC T03682536 NC T03765783 chronic anemia management improving hemoglobin levels reducing transfusion dependence supporting patients with beta-thalassemia supporting patients with myelodysplastic syndromes |
| gptkbp:developed_by |
gptkb:Acceleron_Pharma
|
| gptkbp:formulation |
lyophilized powder for reconstitution
|
| https://www.w3.org/2000/01/rdf-schema#label |
Luspatercept
|
| gptkbp:indication |
gptkb:myelodysplastic_syndromes
gptkb:Footballer |
| gptkbp:ingredients |
C22 H29 N3 O5 S
Luspatercept-aamt |
| gptkbp:invention |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:manager |
subcutaneous
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:Japan gptkb:United_States gptkb:Native_American_tribe brand name Reblozyl |
| gptkbp:related_to |
Hematology
Anemia treatment Erythropoiesis |
| gptkbp:research_focus |
biologics
therapeutic proteins red blood cell production TGF-beta signaling hematologic diseases |
| gptkbp:safety_features |
generally well tolerated
risk of hypersensitivity reactions risk of thromboembolic events monitoring required for blood pressure risk of injection site reactions |
| gptkbp:serves |
gptkb:fandom
|
| gptkbp:shelf_life |
24 months
|
| gptkbp:side_effect |
fatigue
headache nausea hypertension diarrhea |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
anemia due to chronic disease
|
| gptkbp:type_of |
1393700-09-0
|